Cargando…

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers

The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherny, N I, Sullivan, R, Dafni, U, Kerst, J M, Sobrero, A, Zielinski, C, Piccart, M J, Bogaerts, J, Tabernero, J, Latino, N J, de Vries, E G E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115817/
https://www.ncbi.nlm.nih.gov/pubmed/27900206
http://dx.doi.org/10.1136/esmoopen-2016-000100
_version_ 1782468576765018112
author Cherny, N I
Sullivan, R
Dafni, U
Kerst, J M
Sobrero, A
Zielinski, C
Piccart, M J
Bogaerts, J
Tabernero, J
Latino, N J
de Vries, E G E
author_facet Cherny, N I
Sullivan, R
Dafni, U
Kerst, J M
Sobrero, A
Zielinski, C
Piccart, M J
Bogaerts, J
Tabernero, J
Latino, N J
de Vries, E G E
author_sort Cherny, N I
collection PubMed
description The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies for reimbursement. From its inception the ESMO-MCBS Working Group has invited questions and critiques to promote understanding and to address misunderstandings regarding the nuanced use of the scale, and to identify shortcomings in the scale to be addressed in future planned revisions and updates. The ESMO-MCBS V.1.0 has attracted many questions regarding its development, structure and potential applications. These questions, together with responses from the ESMO-MCBS Working Group, have been edited and collated, and are herein presented as a supplementary resource.
format Online
Article
Text
id pubmed-5115817
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51158172016-11-29 ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers Cherny, N I Sullivan, R Dafni, U Kerst, J M Sobrero, A Zielinski, C Piccart, M J Bogaerts, J Tabernero, J Latino, N J de Vries, E G E ESMO Open Review The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies for reimbursement. From its inception the ESMO-MCBS Working Group has invited questions and critiques to promote understanding and to address misunderstandings regarding the nuanced use of the scale, and to identify shortcomings in the scale to be addressed in future planned revisions and updates. The ESMO-MCBS V.1.0 has attracted many questions regarding its development, structure and potential applications. These questions, together with responses from the ESMO-MCBS Working Group, have been edited and collated, and are herein presented as a supplementary resource. BMJ Publishing Group 2016-10-18 /pmc/articles/PMC5115817/ /pubmed/27900206 http://dx.doi.org/10.1136/esmoopen-2016-000100 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Cherny, N I
Sullivan, R
Dafni, U
Kerst, J M
Sobrero, A
Zielinski, C
Piccart, M J
Bogaerts, J
Tabernero, J
Latino, N J
de Vries, E G E
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
title ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
title_full ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
title_fullStr ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
title_full_unstemmed ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
title_short ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
title_sort esmo - magnitude of clinical benefit scale v.1.0 questions and answers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115817/
https://www.ncbi.nlm.nih.gov/pubmed/27900206
http://dx.doi.org/10.1136/esmoopen-2016-000100
work_keys_str_mv AT chernyni esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT sullivanr esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT dafniu esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT kerstjm esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT sobreroa esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT zielinskic esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT piccartmj esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT bogaertsj esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT taberneroj esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT latinonj esmomagnitudeofclinicalbenefitscalev10questionsandanswers
AT devriesege esmomagnitudeofclinicalbenefitscalev10questionsandanswers